SAGA Diagnostics
- Industry
- Medical Laboratories & Imaging Centers
- Founded Year
- 2016
- Headquarters
- Lund, Sweden
- Employee Count
- 73
Key People
- Peter Collins - CEO
- Roopom Banerjee - Executive Chairman
- Anthony George - Co-founder, CTO, and Board Member
- Christina Garcia - VP Compliance
- Brian Krueger, PhD - VP Technology Development
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in MedTech and diagnostics.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: SAGA Diagnostics addresses a critical need for ultra-sensitive cancer diagnostics and monitoring.
The ability to detect cancer mutations at extremely low levels (down to 0.001% mutant allele fraction) fulfills a significant unmet need in oncology diagnostics.
- Competition
-
Aspect: Somewhat crowded
Summary: The liquid biopsy market has several established players, but SAGA's technology offers unique advantages.
Competitors like Foundation Medicine and Guardant Health are present, but SAGA's proprietary technologies offer superior sensitivity, potentially providing a competitive edge.
- Technical Challenge
-
Aspect: Predictable
Summary: The technical challenges are well-defined and manageable with current technologies.
SAGA's proprietary platforms, such as SAGAsafe and SAGAseq, are based on established technologies like digital PCR and next-generation sequencing, indicating predictable technical pathways.
- Patent
-
Aspect: Strong
Summary: SAGA Diagnostics holds strong intellectual property in ultra-sensitive mutation detection.
The proprietary nature of SAGA's technologies, capable of detecting mutations at 0.001% mutant allele fraction, is likely protected by strong patents, enhancing market position.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.
With a total funding of approximately $18M from investors like Segulah Medical Acceleration and Hadean Ventures, SAGA is well-positioned financially to execute its growth plans.
- Regulatory
-
Aspect: 510k/PMA
Summary: SAGA is progressing through regulatory pathways for its diagnostic products.
Efforts towards ISO accreditation and CE-IVD marking indicate a commitment to meeting regulatory standards, essential for market entry and adoption.
Opportunity Rollup
- Odds of Success
- 3.5
- Peak Market Share
- 4.4
- Segment CAGR
- 1.9%
- Market Segment
- In Vitro Diagnostics
- Market Sub Segment
- Liquid Biopsy
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.66 |
| 3 | 1.54 |
| 4 | 3.08 |
| 5 | 4.40 |
Key Takeaway
SAGA Diagnostics, with its ultra-sensitive liquid biopsy technologies, is well-positioned to address the growing demand for non-invasive cancer diagnostics, despite facing a competitive market landscape.